Related posts
S&P, Dow hit records, tech soarsThis summary was created by AI, based on 2 opinions in the last 12 months.
Atrion Corp (ATRI-Q) has recently garnered attention from experts as it appears poised for significant growth and value generation. Two distinct reviews highlighted its strong performance, with an impressive rise of up to 32% and 30%, respectively. The company's asset-light structure has been noted as a key advantage, as its current assets surpass total liabilities, allowing for flexible cash allocation. However, the recent announcement of the acquisition at $460 has raised concerns among analysts, who perceive the stock to be undervalued, estimating a worth between $600 and $800. This discrepancy has led to speculations that the decision was influenced by the aging owners’ desire to retire, raising questions about the strategic direction of the firm moving forward.
Recently, they announced they were being bought out at $460, which angers him between the stock is worth $600-800. He suspects the aging owners just wanted to retire and get out of the business, so they sold.
They make medical supplies, like lens cases for contact lenses. Shares plunged this year due to high interest rates, so their customers didn't buy much from them. But when those customers finish working through their existing inventory, they will order from ATRI again. Trades at only 20x PE, and pay s a 2.5% dividend, which rising 10% annually except this year.
Small caps tend to be less liquid and therefore may have higher betas, although this one is low at 6.1, because it doesn't trade a lot. It makes all kinds of medical devices that none of the big guys want to manufacture. A good entry point would be around $50. This is one you want to hold for the long run.
(A Top Pick Jan 15/16. Up 44.32%.) A tiny little company out of Texas that makes things in the healthcare sector that nobody else wants to create, such as little catheters, IV tubes, cases for contact lenses, etc. His fear is that this company could get bought out because the CEO is getting into his 60s, and succession would be a risk. He wouldn’t buy at this price as it is a little overpriced. Buy on weakness.
(A Top Pick April 4/16. (Actually Jan 15/16.) Up 0.65%.) A little, small medical device company that handles products that larger companies don’t want to be bothered with. It continues to grow very well in the little niches that nobody else wants to do. The dividend has been growing roughly at a 20% clip. Earnings are supposed to be between $15 and $20.
Atrion Corp is a American stock, trading under the symbol ATRI-Q on the NASDAQ (ATRI). It is usually referred to as NASDAQ:ATRI or ATRI-Q
In the last year, 2 stock analysts published opinions about ATRI-Q. 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Atrion Corp.
Atrion Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Atrion Corp.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
2 stock analysts on Stockchase covered Atrion Corp In the last year. It is a trending stock that is worth watching.
On 2024-08-21, Atrion Corp (ATRI-Q) stock closed at a price of $459.93.
Bought out by another company in August. Asset-light company, where current assets were greater than total liabilities. This type of company is very flexible, allocating cash any way they want.